{"prompt": "['Protocol VX18-445-109, Version 1.0', 'Page 48 of 60', '13', 'PROCEDURAL, ETHICAL, REGULATORY, AND ADMINISTRATIVE', 'CONSIDERATIONS', '13.1', 'Adverse Event and Serious Adverse Event Documentation, Severity', 'Grading, and Reporting', '13.1.1', 'Adverse Events', '13.1.1.1', 'Definition of an Adverse Event', 'An AE is defined as any untoward medical occurrence in a subject during the study; the event', 'does not necessarily have a causal relationship with the treatment. This includes any newly', 'occurring event or worsening of a pre-existing condition (e.g., increase in its severity or', 'frequency) after the ICF is signed.', 'An AE is considered serious if it meets the definition in Section 13.1.2.1.', '13.1.1.2', 'Clinically Significant Assessments', 'Study assessments including laboratory tests, ECGs, PEs, and vital signs will be assessed and', 'those deemed to have clinically significant worsening from baseline will be documented as an', 'AE. When possible, a clinical diagnosis for the study assessment will be provided, rather than the', 'abnormal test result alone (e.g., urinary tract infection, anemia). In the absence of a diagnosis,', 'the abnormal study assessment itself will be listed as the AE (e.g., bacteria in urine or decreased', 'hemoglobin).', 'An abnormal study assessment is considered clinically significant if the subject has 1 or more of', 'the following:', 'Concomitant signs or symptoms related to the abnormal study assessment', 'Further diagnostic testing or medical/surgical intervention', 'A change in the dose of study drug or discontinuation from the study', 'Repeat testing to determine whether the result is abnormal, in the absence of any of the above', 'criteria, does not necessarily meet clinically significant criteria. The determination of whether the', 'study assessment results are clinically significant will be made by the investigator.', 'A laboratory value that is Grade 4 will not automatically be an SAE. A Grade 4 laboratory value', \"will be an SAE if the subject's clinical status indicates a life-threatening AE.\", '13.1.1.3', 'Documentation of Adverse Events', 'All AEs will be collected from the time the ICF is signed until the subject completes study', 'participation, as defined in Section 9.1.7', 'All subjects will be queried, using nonleading questions, about the occurrence of AEs at each', 'study visit. When possible, a constellation of signs and/or symptoms will be identified as', '1 overall event or diagnosis. All AEs for enrolled subjects will be recorded in the CRF and', 'source document. AEs for subjects who are screened but not subsequently enrolled will be', \"recorded only in the subject's source documents. The following data will be documented for\", 'each AE:', 'Description of the event', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 49 of 60', 'Classification of \"serious\" or \"nonserious\"', 'Date of first occurrence and date of resolution (if applicable)', 'Severity', 'Causal relationship to study drug(s)', 'Action taken', 'Outcome', 'Concomitant medication or other treatment given', '13.1.1.4', 'Adverse Event Severity', 'The investigator will determine and record the severity of all serious and nonserious AEs. The', 'guidance available at the following website will be consulted: Common Terminology Criteria for', 'Adverse Events (CTCAE), Version 5.0, Cancer Therapy Evaluation Program,', 'http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (Accessed', 'February 2019). AEs of CTCAE Grades 4 and 5 will be documented as \"life-threatening.\" When', 'considering the severity of an AE in a pediatric subject, the investigator will consider that', 'reference ranges for pediatric clinical laboratory parameters may differ from those in the', 'CTCAE. The severity of an AE described by a term that does not appear in the CTCAE will be', 'determined according to the definitions in Table 13-1.', 'Table 13-1', 'Grading of AE Severity', 'Classification', 'Definition', 'Mild (Grade 1)', 'Mild level of discomfort and does not interfere with regular activities', 'Moderate (Grade 2)', 'Moderate level of discomfort and significantly interferes with regular activities', 'Severe (Grade 3)', 'Significant level of discomfort and prevents regular activities', 'Life-threatening (Grade 4)', 'Any adverse drug event that places the subject, in the view of the investigator, at', 'immediate risk of death', 'AE: adverse event', '13.1.1.5', 'Adverse Event Causality', 'Every effort will be made by the investigator to assess the relationship of the AE, if any, to the', 'study drug(s). Causality will be classified using the categories in Table 13-2.', 'Table 13-2', 'Classifications for AE Causality', 'Classification', 'Definition', 'Related', 'There is an association between the event and the administration of investigational', 'study drug, a plausible mechanism for the event to be related to the investigational', 'study drug and causes other than the investigational study drug have been ruled out,', 'and/or the event reappeared on re-exposure to the investigational study drug.', 'Possibly related', 'There is an association between the event and the administration of the', 'investigational study drug and there is a plausible mechanism for the event to be', 'related to investigational study drug, but there may also be alternative etiology, such', \"as characteristics of the subject's clinical status or underlying disease.\", 'Unlikely related', 'The event is unlikely to be related to the investigational study drug and likely to be', 'related to factors other than investigational study drug.', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}